A Double-Blind Efficacy and Safety Study of Evacetrapib Followed by an Open-Label Extension in Japanese Patients With Primary Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Evacetrapib (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 01 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 22 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.